[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][O][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][C][=C][Branch2][Ring1][=C][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C@H1][C@@H1][Branch1][P][C@H1][Branch1][=N][C@@H1][Branch1][=Branch2][C@H1][Branch1][Ring2][O][Ring1][=Branch1][S][C][O][O][O][Cl]"}, {"from": "gpt", "value": "The molecule is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI \u226527 kg/m2. Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as [canagliflozin] and [dapagliflozin], but its potency in inhibiting SGLT1 is >10-fold higher than its predecessors. The added inhibition of intestinal SGLT1 delays glucose absorption in the distal small intestine and colon, thereby reducing post-prandial glucose levels.  Sotagliflozin was approved in the EU under the brand name \"Zynquista\" on April 26, 2019. A similar approval has also been sought in the US, but the FDA has since published a proposal to refuse the approval on the grounds that the data submitted did not show that it was safe under the proposed conditions of use."}]